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Abstract
Recent studies have characterized the ABC half-transporter associated with mitoxantrone resistance in human cancer cell lines. Encoded
by the ABCG2 gene, overexpression confers resistance to camptothecins, as well as to mitoxantrone. We developed four polyclonal
antibodies against peptides corresponding to four different epitopes on the mitoxantrone resistance-associated protein, ABCG2. Three
epitopes localized on the cytoplasmic region of ABCG2 gave rise to high-affinity antibodies, which were demonstrated to be specific for
ABCG2. Western blot analysis of cells with high levels of ABCG2 showed a single major band of the expected 72-kDa molecular size of
ABCG2 under denaturing conditions. Immunoblot analysis performed under non-reducing conditions and after treatment with cross-linking
reagents demonstrated a molecular weight shift from 72 kDa to several bands of 180 kDa and higher molecular weight, suggesting detection
of dimerization products of ABCG2. Evidence of N-linked glycosylation was also obtained using tunicamycin and N-glycosidase F. Finally,
both by light, fluorescence and electron microscopic immunohistochemical staining, we demonstrate cytoplasmic and predominantly plasma
membrane localization of ABCG2 in cell lines with high levels of expression. Plasma membrane staining was observed on the surface of the
chorionic villi in placenta. These results support the hypothesis that ABCG2 is an ABC half-transporter that forms dimers in the plasma
membrane, functioning as an ATP-dependent outward pump for substrate transport.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
A new drug resistance gene, which confers high levels of
resistance to mitoxantrone, anthracyclines, and several
camptothecins, has been identified as an ABC half-trans-
porter. Reported from several laboratories, it was termed
MXR, for mitoxantrone resistance gene, in our hands [1];
BCRP, for breast cancer resistance protein, by Doyle et al.
[2]; and ABCP, for ABC transporter expressed in placenta,
by Allikmets et al. [3]. Overexpression of this transporter
leads to reduced accumulation of its substrates, which
include mitoxantrone, anthracyclines, several camptothe-
cins, rhodamine 123, prazosin, and Lysotracker Green
[4,5]. The human gene nomenclature committee (HUGO)
has recommended that this gene be identified as ABCG2 [6].
The mouse orthologue for ABCG2, Abcg2 (abcp1), is over-
expressed in drug-resistant cell lines in which the ortho-
logues for MDR-1 and MRP are deleted [7]. Overexpression
of Abcg2 (abcp1) resulted whether the selecting agent was
topotecan, adriamycin, or mitoxantrone. Recently, it was
determined that a mutation at amino acid 482, in the third
transmembrane domain, conferred some of the disparate
substrate specificity observed in drug-resistant cells [8]. An
arginine is encoded at amino acid position 482 in cells
containing wild-type ABCG2, conferring a narrower sub-
strate specificity with resistance primarily to mitoxantrone
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and the camptothecins. A threonine or glycine encoded at
amino acid 482 results in a gain of function with the
anthracyclines and rhodamine 123 added as substrates.
The ABCG2 gene encodes a 655-amino-acid transmem-
brane protein, with a domain organization characteristic of
ABC half-transporters [9]. These proteins typically contain
six transmembrane segments and one ATP binding domain,
and require dimerization with a partner protein to become
functional transporters [10]. Half-transporters are in gen-
eral localized to intracellular compartments, such as the
endoplasmatic reticulum for TAP1/TAP2 [11,12]; peroxi-
somes for the ALD subfamily [13]; and the mitochondria
for M-ABC1 and ABC7 [14,15]. The ‘‘full-size’’ ABC
transporters, on the other hand, among which are P-
glycoprotein and MRP, are typically situated in the plasma
membrane, and are about twice the size of half-trans-
porters, with 12–17 membrane spanning segments and
two ATP binding sites [10].
Studies to date suggest that ABCG2 is a potent, new
mechanism for conferring multiple drug resistance. To better
characterize the protein, to define and localize the functional
transport unit, and to define its role in clinical oncology, we
undertook to develop and characterize a panel of polyclonal
antibodies against several epitopes on ABCG2.
2. Materials and methods
2.1. Cell culture
All cell lines were grown in IMEM supplemented with
glutamine (2 mM), fetal calf serum (10%), penicillin (100
u/ml), and streptomycin (100 Ag/ml). Drug-resistant cells
were maintained in the presence of the selecting drugs.
The S1-M1-80 cells were generated in our lab by expos-
ing the S1-M1-3.2 colon carcinoma cell line (established
by Rabindran et al. [16]) to increasing concentrations of
mitoxantrone. The S1-M1-80 cell line was maintained in
80 AM mitoxantrone [1]. The MCF-7-resistant sublines
were derived by stepwise selection from parental MCF-7
breast carcinoma cells. The MCF-7 AdVp3000 cells were
selected from MCF-7 parental cells and were cultured in
5.5 AM adriamycin plus 5.5 AM verapamil [17]. The
MCF-7 FLV1000 cell line was selected in 1 AM flavopir-
idol as described by Robey et al. [18]. The MCF-7 MX
cell line was obtained from Young et al. [19] and
independently selected and cultured in mitoxantrone at
600 ng/ml.
2.2. Peptide synthesis
Peptide synthesis was accomplished manually using a
stepwise Fmoc/t-Bu solid-phase peptide synthesis procedure
[20] on TentaGel S RAM resin (Rapp Polymers, Tu¨bingen,
Germany). Following peptide synthesis and workup, the
product was characterized by liquid-chromatography mass
spectrometry. The peptide sequences and predicted local-
ization within ABCG2 are indicated in Fig. 1.
2.3. Antibody production
Antibodies were obtained by immunizing New Zealand
White rabbits with KLH-conjugated peptide (100 Ag peptide
per injection). Pre-immune bleeds were taken from all
rabbits before the first injection. After immunization, bleeds
were drawn from the ear vein at weeks 6, 8, and 10. The
rabbits were boosted twice with the same peptide as used for
the primary injection at 4-week intervals. We have named
the antibodies after the rabbit identification number. The
titer of each antibody was tested by an enzyme-linked
immunosorbent assay (ELISA) using the immunizing pep-
tide on the solid phase.
2.4. Cross-linking
Chemical cross-linking was performed in vivo on intact
cells. After incubation at room temperature for 30 min with
the cross-linking agents disuccinimidylsuberate (DSS) or
dithiobis[succinimidylpropionate] (DSP) at 2 mM final
concentration, the reaction was terminated by addition of
Tris–HCl (pH 8) to 20 mM [14], and the cells were lysed. In
enzymatic cross-linking experiments, ABCG2 containing
microsomes were treated with tissue transglutaminase at
20 Ag/ml at 37 jC for 30 min, before electrophoretic
analysis [21].
Fig. 1. Predicted secondary structure of ABCG2. The cartoon shows the
positions of the four epitopes chosen for antibody production within the
sequence of ABCG2. Also indicated is the ATP binding site (the Walker A
and B motifs) and the putative N-glycosylation sites. The peptide sequences
are: 405 (56–70): RKPVEKEILSNINGI; 391 (150–167): TTMTNHE-
KNERINRVIEE; 407 (208–221): SLDEPTTGLDSSTA; 426 (608–622):
CTGEEYLVKQGIDLS.
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2.5. Glycosylation analysis
To assess the level of glycosylation, two complementary
methods were employed:
1) Enzymatic deglycosylation of ABCG2-containing mi-
crosomes with 2 I.U. N-glycosidase F was performed at
37 jC for 12 h [14], or
2) Cells were grown in the absence or presence of
tunicamycin, which inhibits de novo N-linked glyco-
sylation, at 5 Ag/ml for 3 days [22].
2.6. Western blot analysis of proteins
Microsomal membranes (50 Ag of protein) were incu-
bated in SDS loading buffer (2% SDS, 10% glycerol, 1%
beta-mercaptoethanol, 5 ppm bromophenol blue, 125 mM
MOPS, pH 6.8) for 20 min without boiling. For experiments
under non-reducing conditions, beta-mercaptoethanol was
omitted from the loading buffer. The extracts were loaded
onto an 8% (w/v) SDS–polyacrylamide gel and subjected to
electrophoresis [23]. After electro-transfer onto nitrocellu-
lose membranes (Bio-Rad, Hercules, CA), the blots were
blocked with Tris-buffered saline containing 0.05% (v/v)
Tween-20 and 5% (w/v) non-fat dry milk. Probing was
performed overnight at 4 jC with the polyclonal anti-
ABCG2 antibodies (in dilutions 1:500–1:3000), which
were raised against 14–18-mer peptide fragments of
ABCG2. After washing the membranes four times in TST
(10 mM Tris–HCl, 150 mM NaCl, 0.05% Tween-20, pH
7.5), a secondary horseradish peroxidase-conjugated donkey
anti-rabbit antibody (Affinity Bioreagents, Golden, CO) was
applied for 1 h (dilution 1:2000) followed by enhanced
chemiluminescence detection (NEN, Boston MA) with
exposure on Kodak X-OMAT AR autoradiography film to
visualize immunoreactive bands.
2.7. Immunoprecipitation
For immunoprecipitation, microsomal membranes were
solubilized in RIPA buffer (150 mM NaCl, 1% Triton X-
100, 0.1% SDS, 50 mM Tris–HCl, protease inhibitors:
pepstatin A 10 Ag/ml, leupeptin 10 Ag/ml, aprotinin 5 Ag/
ml, PMSF 2 mM) for 30 min at 4 jC. Affinity-purified
rabbit-anti-ABCG2 antibody 405 (75 Al) was cross-linked to
a protein A column (total volume: 0.4 ml) with 5 mM DSS
(Seizek Protein A Immunoprecipitation Kit, Pierce, Rock-
ford, IL). The soluble fraction from the RIPA extract was
applied on the column and incubated overnight at 4 jC, end-
over-end. Elution of the immune complexes was performed
according to the protocol (Pierce). The eluted material was
separated on a 7% NuPAGE tris-acetate gel (NOVEX, San
Diego, CA), and silver stained, following the manufacturer’s
protocol (Pharmacia Biotech Silver staining kit, Pharmacia,
Uppsala, Sweden).
2.8. Immunohistochemistry
Formalin-fixed paraffin embedded tissue blocks were cut
into 5-Am sections. The sections were baked at 60 jC,
deparaffinized in xylene and ethanol, microwaved for 5 min
until boiling in Citra Plus (BioGenex), and then microwaved
for another 15 min at low power. Tissue sections were
quenched in 3% H2O2, and subsequently incubated in 5%
goat serum for 20 min. An avidin–biotin block (Vector
Laboratories, Burlingame, CA) was incorporated. Anti-
ABCG2 polyclonal antibody (405, dilution 1:2500) was
added to the section, and the slides were incubated for 2 h
at room temperature. A biotinylated secondary antibody
(goat anti-rabbit) was applied and slides were incubated
for 30 min at room temperature. An avidin–biotin–perox-
idase complex was formed and slides were incubated a
further 30 min. Subsequently, 3,3V-diaminobenzidene
(DAB, Sigma, St. Louis, MO) was used to detect the bound
peroxidase. On all samples, a negative sample control
(rabbit immunoglobulins, DAKO, Carpinteria, CA) was also
performed, and a positive control cell line (MCF7 MX100)
was used throughout.
2.9. Immunofluorescence confocal microscopy
Cells (105/ml) were grown in phenol-red free IMEM for
48 h in eight-well glass chamberslides (Nunc, Roskilde,
Denmark) before washing with PBS. After fixation in 1:1
methanol/ethanol for 1 min at room temperature, the slides
were washed 10 min in PBS, and this washing step was
repeated three times. Then the slides were incubated with
2% human AB serum (Sigma) for 2 h at room temperature
and gentle shaking. Probing with the polyclonal antibody
405 at dilutions 1:3000–1:6000 was performed at 4 jC
overnight. After washing four times 10 min with PBS, the
secondary antibody, FITC-labeled pig-anti rabbit (DAKO,
Denmark), was added for 1 h at a 1:100 dilution. A Zeiss
LSM 410 confocal laser scanning microscope equipped with
a 150-mW Omnichrome Ar–Kr laser exciting at 488 nm
was used for excitation of the fluorescein label, and the
emitted light passed through a 515- to 540-nm band-pass
filter. Images were stored online to a ZIP disk (Iomega) and
analyzed off-line in Paint Shop Pro v. 6.02 (Jasc, Eden
Prairie, MN).
2.10. Immuno-electron microscopy
Cells were plated in 10 cm Petri dishes and grown in
phenol-red free IMEM medium for 48 h before the medium
was removed by aspiration. Then, the cells were washed
with 0.1 M ice-cold phosphate buffer (PBS) and scraped
from the surface of the culture flask. The cell suspension
was washed once with PBS, centrifuged, fixed for 1 h with
4% (w/v) paraformaldehyde in 0.1 M PBS, and then washed
again with PBS. The cell pellet was embedded in 15% (w/v)
gelatin (Sigma, G-9382) in 0.1 M PBS at 37 jC for 10 min,
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and then centrifuged at 4000 rpm for 5 min. After the gelatin
solidified, it was cut into small pieces which were infiltrated
with poly-vinyl-pyrolidone (PVP)-sucrose, and then frozen
in liquid nitrogen [24]. Ultrathin sections were cut on a
Leica EMFCS.
For immunostaining, the rabbit polyclonal antisera 405
and 391 were diluted 1:10,000 (after initial titration experi-
ments with different antibody dilutions), goat anti-rabbit
IgG conjugated to 1 nm colloidal gold particles (Aurion,
Wageningen, The Netherlands) was diluted 1:300, and
Fig. 2. Immunoblot screening of the four anti-sera 405, 407, 391, 426. (A) Antisera in ABCG2-overexpressing cell lines. (B) Anti-serum 405, which has or has
not been preadsorbed with the peptide fragment used for immunization. (C) Glycosylation analysis: Treatment with either PNG F (N-glycosidase F) or
tunicamycin reduces the apparent molecular weight of ABCG2 to its non-glycosylated form.
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Protein A 5 nm particles (BioCell, Cardiff, England) were
applied at a 1:75 dilution. Sections were blocked by
incubation in 20 mM glycine and 0.1% (w/v) skim milk
powder in PBS for 15 min, followed by incubation with
primary antibody overnight at 4 jC. After washing with
0.1% (w/v) skim milk in PBS for 20 min, the sections were
incubated with goat anti-rabbit 1 nm gold/Protein A in 0.1%
(w/v) skim milk/PBS containing 0.06% (v/v) polyethylene-
glycol and 2.2% (w/v) fish gelatin for 2 h. Sections were
washed with 0.1% (w/v) skim milk in PBS for 30 min,
postfixed in 2% (w/v) glutaraldehyde and washed again
with distilled water before silver enhancement (R-GENT,
Aurion, Wageningen, The Netherlands) for 45 min. Finally,
the sections were contrasted in uranyl acetate for 5 min
followed by a 5-min incubation in acidic uranyl acetate/
methyl cellulose [25]. Control experiments included pre-
immune serum, primary antibody adsorbed to the immuniz-
ing peptide, as well as omitting the primary antibody.




From the predicted secondary structure of ABCG2,
BLAST [26] searches, and antigenicity plots (not shown),
we chose four different epitopes on ABCG2 for peptide
synthesis and antibody production. The epitopes are indi-
cated in Fig. 1 and correspond to a region just before the N-
terminal Walker A motif (56–70: RKPVEKEILSNINGI),
an area between the Walker A and B domain (150–167:
TTMTNHEKNERINRVIEE), a peptide including theWalker
B site (208–221: SLDEPTTGLDSSTA), and an amino acid
stretch which is part of a large extracellular loop (608–622:
CTGEEYLVKQGIDLS) close to the C-terminal. A BLAST
search of the GenBank protein database indicates that all four
of the peptides have 100% identity only with ABCG2. The
sequence near the Walker A motif (56–70: RKPVEKEILS-
NINGI) and the sequence between Walker A and B (150–
167: TTMTNHEKNERINRVIEE), are so distinct that even
allowing four mismatches, the only hits retrieved were the
same gene, AF098951 (BCRP) and AF103796 (ABCP1).
3.2. Immunoblot analysis
Results of immunoblot analysis with the panel of four
antisera are shown in Fig. 2A: 405 (peptides 56–70); 391
(peptides 150–167); and 407 (peptides 208–221). The
fourth antiserum, 426 (peptides 608–622) failed to generate
a specific signal, and results obtained with this antibody are
not shown in subsequent experiments. The 405, 407, and
391 antibodies all detect a 72-kDa band in membrane
extracts from ABCG2 overexpressing (by Northern blot)
cells: MCF-7 MX8 (intermediate ABCG2 expression), and
MCF-7 MX100 (high ABCG2 expression). The 72-kDa
band found corresponds well to the predicted molecular
weight of ABCG2. No bands were detected in control lanes
with microsomal membranes from cells with very low
levels of ABCG2 expression, MCF-7 wt, as measured by
Northern blot. Specificity of the antibodies was further
confirmed using pre-immune serum (data not shown) and
anti-serum preadsorbed with the immunizing peptide for 1
h at 37 jC. Only the result with the 405 preadsorbed
antibody is shown in Fig. 2B; results with the other two
specific antibodies were comparable. The 405 antibody,
raised against a peptide corresponding to the region 5Vto
Fig. 3. Apparent dimerization of ABCG2. (A) Chemical cross-linking with DSS, (B) the effect of reduced vs. non-reduced SDS-PAGE conditions, and (C)
silver-stained gel after immuno-precipitation of S1-M1-80 membranes.
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Fig. 4. Confocal microscopic images of immunofluorescence assay using the two anti-sera 391 and 405 on S1 and MCF-7 parental cells and on ABCG2-positive MCF-7 AdVp3000 and S1-M1-80 cells. ABCG2







































the Walker A site, gave a higher level of signal than the
other antisera.
To assess whether ABCG2 was post-translationally
modified by addition of oligosaccharide at one or both of
its potential N-linked glycosylation sites, immunoblotting
was performed on microsomes treated with N-glycosidase F,
and on cells grown in the presence of tunicamycin, which
inhibits N-glycosylation. As shown in Fig. 2C, both treat-
ments lead to a significant reduction in the apparent molec-
ular mass of ABCG2, suggesting that ABCG2 does contain
N-linked oligosaccharide, probably at both the putative
glycosylation sites.
3.3. Detection of dimerization products
The chemical cross-linkers DSP and DSS were used to
link proteins in close proximity, 12 and 11.4 A˚, respectively.
Both reagents induced formation of high-molecular-weight
products, which were detected by the anti-ABCG2 405
antibody. Three bands, with molecular weight 180 kDa or
greater, were identified in cell lysates from MCF-7
AdVp3000, but not the parental MCF-7 cells (Fig. 3A, only
results with DSS are shown). The formation of these bands
was dependent on the presence of the cross-linking agent,
DSS. Interestingly, similar high-molecular-weight bands
were also observed when the cell lysates were run in
SDS-PAGE gels under non-reducing conditions (without
DTT and beta-mercaptoethanol) as shown in Fig. 3B. These
bands were not detected when the gel was run under
reducing conditions. Identical results, that is, the appearance
of a high-molecular-weight complex that disappeared after
treatment with beta-mercaptoethanol, were obtained with
enzymatic, transglutaminase-catalyzed cross-linking of
ABCG2-containing S1-M1-80 membranes (data not
shown). The high-molecular-weight bands suggest that
ABCG2 may oligomerize with other proteins, and most
likely, with itself. The latter notion is supported by the
immunoprecipitation experiment depicted in Fig. 3C. Here,
only a single MW f 140-kDa band, corresponding to a
possible ABCG2 dimer, appears on the silver-stained gel
after elution from the protein-A-antibody immunoprecipita-
tion column.
3.4. Immunofluorescence confocal microscopy
Previous immunohistochemical studies in the selected
cell lines using the 405 antibody suggested a plasma
membrane localization for ABCG2 [4,27]. We asked
whether similar results would be obtained with an immuno-
fluorescence technique using sensitive confocal microscopy.
Fig. 5. Immunohistochemistry on paraffin sections of two mid-term, normal placentas. The staining was performed as described in Materials and Methods.
Antibodies 391 and 405 at 1:3000 dilution were applied as well as control staining with non-immune serum (NS). Note staining on the cell surface of the
synchitiotrophoblast cell layer of the chorionic villi.
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Fig. 4 displays the membrane and intracellular localization
of ABCG2 in S1-M1-80 and MCF-7 AdVp3000 cell lines
by confocal microscopy using immunofluorescence. Similar
localization of ABCG2 was observed with MCF-7 FLV1000
and MCF-7 MX cells. Only background levels of ABCG2
were detected in the parental cell lines, S1 wt and MCF-7
Fig. 6. Immuno-electron microscopy with 1 nm immunogold. The top panels (A,B,C) have been stained with anti-ABCG2 antibody 391, and the lower panels
(D,E,F) with the anti-ABCG2 antibody 405. Wild-type cells stained consistently negative (A,D), while drug-resistant MCF-7 MX cells showed labeling of the
cell membrane (B,E). This specific membrane labeling was eliminated by blocking with the antibody-specific peptide (C,F). Magnification  16,000 in all
panels. Abbreviations: pm, plasma membrane; mv, microvillus (microvilli); n, nucleus; j, junction; ly, lysosome. Panels A and D show part of the cell surface of
one cell, while B, C, E and F show microvilli-containing opposing surfaces of two cells. The big dense blobs on A are chromagen deposits (staining artifacts)
that can be observed in cells in which antibody has not been added.
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wt. Control experiments with primary antibody preadsorbed
with the peptide used for immunization, as well as incuba-
tion with pre-immune serum only, showed no specific
labeling (data not shown).
3.5. Immunohistochemistry
Before studies aimed at determination of the normal
tissue expression pattern, we evaluated the ability of the
antibodies to detect ABCG2 in tissues fixed in paraffin.
Since high levels of expression were observed by Northern
blot in placenta [3], we used that tissue to assess the ability
of these antibodies to detect ABCG2 in paraffin-embedded
samples. As shown in Fig. 5, membrane staining is noted on
the surface of synchitiotrophoblastic cells of the chorionic
villi. The 405 antibody, as in the immunoblot analysis, gave
a stronger signal than the 391 antibody. Plasma membrane
staining was seen with both antibodies, as shown in the
insets. Peptide competition studies demonstrated loss of
specific antibody staining (data not shown), and non-
immune serum (NS) showed consistent negative staining.
3.6. Immuno-electron microscopy
Ultrathin cryosections of MCF-7 cells were stained with
1 nm immunogold for the evaluation of ABCG2 antigen
expression using both anti-ABCG2 antibodies 391 and 405.
Wild-type MCF-7 cells stained consistently negative (Fig.
6A,D), while mitoxantrone-resistant MCF-7 MX cells dis-
played a distinct labeling on the cell surface membrane (Fig.
6B,E). This membrane staining was eliminated by adsorp-
tion of the antibody to the corresponding peptide used for
immunization (Fig. 6C,F). Membrane staining was also
observed on intracellular luminae containing slender, micro-
villus-like cell projections (data not shown). In drug-resist-
ant MCF-7 MX cells, cytoplasmic labeling was seen inside
empty-looking vesicles (Fig. 7). The nature of these vesicles
remains unknown since they did not show any resemblance
to lysosomes, Golgi saccules, mitochondria or endoplasmic
reticulum (ER). The latter structures are all stained nega-
tively. No major differences in staining pattern or intensity
could be detected between the two antibodies (Fig. 6) or
between crude serum preparations and affinity-purified anti-
body fractions (data not shown).
In an attempt to evaluate a possible di- or polymerization
of the ABCG2 protein molecules, anti-ABCG2 antibodies
were labeled with protein A to achieve a 1:1 grain/antigen
ratio. Protein A tagging appeared as separate grains in all
positively stained areas (data not shown). Similar results
were obtained with MCF-7 AdVp3000 cells, though the
labeling was less concentrated than what was observed with
MCF-7 MX cells. The latter cells appear to have the highest
expression level of ABCG2 of all cell lines so far tested.
Labeling of S1-M1-80 cells was close to background levels
Fig. 7. (A) Immuno-electron microscopy with antibody 405 and 1 nm immunogold. Magnification  16,000. (B) Conventional electron microscopy for
morphological resolution. Magnification  6,300. ABCG2 antigen expression is seen in cytoplasmic empty-looking vesicles that do not resemble lysosomes,
Golgi saccules, mitochondria or ER. Abbreviations: pm, plasma membrane; ly, lysosome microvillus (microvilli); n, nucleus; j, junction; ly, lysosome.
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suggesting that only high levels of ABCG2 will be detected
by the immuno-electron microscopy.
4. Discussion
To aid in evaluating the mechanism of action and
function of the ABC half-transporter ABCG2 and to facil-
itate its detection in clinical trials, we generated a series of
rabbit polyclonal antibodies. These antibodies were pro-
duced against four predicted peptide epitopes on the
ABCG2 protein. Three of these antibodies, derived from
peptides predicted to be in the cytoplasmic region, proved to
be of high affinity, while no specific binding could be
detected with the fourth antibody. The antibodies confirmed
the expected 72-kDa molecular size of ABCG2. The protein
was shown to be highly glycosylated, probably on both the
putative N-glycosylation sites, and enzymatic deglycosyla-
tion decreased the molecular weight to that found with
ABCG2 expressing Sf9 cells [22]. Cross-linking studies
and electrophoresis under non-reducing conditions suggest
that ABCG2 undergoes dimerization or higher orders of
oligomerization. Both cytoplasmic and plasma membrane
localization were observed by confocal microscopy, by
immunohistochemistry and by immuno-electron microscopy
in drug-selected cell lines with high levels of ABCG2
expression, while no staining was detectable on the cell
surface of parental cells.
The ABC half-transporter MXR (ABCG2) was identified
in human colon carcinoma cells highly resistant to mitox-
antrone. This protein is identical to the breast cancer
resistance associated protein (BCRP), and to the placenta-
specific ABC transporter (ABCP1) [2,3]. The substrate
specificity has been the subject of several studies, which
in accordance have demonstrated high levels of mitoxan-
trone resistance, with cross-resistance to certain camptothe-
cins including topotecan and SN-38 [5,7,28]. Mutation at
amino acid 482 results in a gain of function that produces an
increase in the overlap in substrate specificity with P-
glycoprotein. Yet, there is a lack of sensitivity to most
inhibitors of P-glycoprotein. As such, ABCG2 is a potential
candidate to explain some of the failures of P-glycoprotein
antagonists to improve therapeutic outcome in clinical trials
[29].
The peptides chosen for the antisera corresponded to four
14- to18-mer peptide sequences on ABCG2–3 cytoplasmic
regions near the ATP binding domain and one region
corresponding to a putative extracellular loop. The antibody
405 was generated to sequence RKPVEKEILSNINGI, pep-
tides 56–70, 5V to the Walker A sequence. The antibody 391
was generated to sequence TTMTNHKNERINRVIEE, pep-
tides 150–167, near the C signature region. The antibody
407 was generated to sequence SLDEPTTGLDSSTA, pep-
tides 208–221, including the Walker B site.
One of the most intriguing questions involving ABCG2
is its localization. The three previously known subfamilies
of human half-transporters have intracellular localization.
The TAP1 and 2 genes localize to the ER for their role in the
transport of antigen into the ER for loading onto the major
histocompatibility complex type I (MHCI) [12]. The perox-
isomal transporters ALDP, PMP 70, and PMP 69R localize
to the peroxisome for their role in the transport of lipids for
beta-oxidation [30]. M-ABC1 and ABC7 have a mitochon-
drial localization [14,15]. Thus, it could be expected that
ABCG2 would localize to an intracellular organelle. How-
ever, the 405 antibody has demonstrated plasma membrane
staining by both confocal microscopy and by immunohis-
tochemistry [4,27]. These findings are similar to those
observed with the monoclonal antibody generated against
BCRP [31]. This result was confirmed and extended by the
plasma membrane staining observed by confocal micro-
scopy in MCF-7 AdVp3000 cells with antibodies raised to
peptides from different regions of ABCG2. New results
from immuno-electron microscopy, which are the first of
their kind, support these findings. Further, by immunohis-
tochemistry, both the 391 and the 405 antibodies stain the
plasma membrane in the chorionic villi of the placenta.
However, the decidual cells within the placenta demonstrate
cytoplasmic staining. One possible interpretation of this
result is that the localization may vary, depending upon
the cell type, the level of expression, or potentially upon
dimerization partners.
The question of dimerization is a second intriguing issue
for ABCG2. As a half-transporter, it should dimerize to
form a functional ABC protein, with two ATP binding
domains and two sets of transmembrane regions. Protein
database searches revealed the Drosophila white gene prod-
uct to be the closest match. The product of the white gene is
known to dimerize with that of the brown or scarlet gene, to
transport guanine or tryptophan, precursors for the forma-
tion of eye pigment [32]. The white gene product does not
appear to make a functional homodimer. These conclusions
are based principally upon mutational analysis, and detailed
structural studies of the proteins have not been made. The
fact that transfection studies confirm the ability of ABCG2
to confer a resistant phenotype suggests that homodimers
are in this case functional [22,33]. Studies with ABCG2 in
non-reducing conditions, and following chemical cross-link-
ing, as well as immunoprecipitation experiments, suggest
that dimerization, and possibly higher orders of oligomeri-
zation, may occur. However, the formation of non-specific
protein complexes in the presence of chemical cross-linkers
and under non-denaturating conditions, cannot be excluded.
Kage et al. [34] also reported a high-molecular-weight band
detectable by ABCG2 antibodies under non-reducing con-
ditions and argued that the dimerization of ABCG2 is
dependent upon disulfide bridges. Functional studies, for
example, with cysteine-less mutants would be required to
confirm this hypothesis. Data demonstrating the drug-mod-
ulatable ATPase activity of ABCG2 show that the protein is
catalytically active under reducing conditions [22], which
argues against the dependence on disulfide bridge formation
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for ABCG2 function. The model of SUR in which four
molecules together with the KIR subunits join to form a
functional potassium channel, suggests that the possibility
of multimers should not be excluded [35]. Oligomeric forms
of P-glycoprotein have also been suggested [36].
By immuno-electron microscopy, we confirmed both the
plasma membrane and intracellular localization of ABCG2.
Interestingly, it was not possible to demonstrate di- or
oligomerization of ABCG2 with protein A gold labeling
as only separate grains were observed. This, however, does
not exclude dimerization, and could be due to technical
difficulties, as the relatively large gold particles may have
prevented close approximation of a second large particle on
the dimer.
In summary, we have identified three polyclonal anti-
bodies derived from ABCG2 peptides, one 5V to Walker A,
one including Walker B, and the third between the two, near
the C signature region characteristic of ABC transporters.
All three recognize ABCG2 on immunoblot analysis, and by
immunohistochemical analysis. A fourth antibody made to
recognize a putative extracellular domain failed to hybridize
to ABCG2 on immunoblot, or by immunohistochemistry.
Further studies are needed to determine whether other
dimerization partners for ABCG2 can be found. High levels
of expression on the plasma membrane of synchitiotropho-
blastic cells of the chorionic villi of the placenta suggest a
role for protection of the developing fetus from xenobiotics.
Numerous questions regarding the role of ABCG2 in normal
physiology and in clinical oncology remain. Recently, it has
been reported to be responsible for the ‘‘side-population’’
phenotype of human stem cells [37]. The early identification
of inhibitors suggests the feasibility of drug resistance
reversal studies, and guarded optimism for improved che-
motherapeutic efficacy.
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